A Phase 1, Open Label, Dose Escalation Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Subjects With Relapsed or Refractory Solid Tumors
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009306/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of
subjects with relapsed or refractory solid tumors.
提供机构：
Vivli
创建时间：
2023-09-27
